Retrospective cohort study | Sequential Intravesical Gemcitabine and Docetaxel seem effective for high-risk BCG-naïve nonmuscle-invasive bladder cancer. 2 Aug, 2022 | 11:58h | UTC Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin–Naïve High-Risk Nonmuscle-Invasive Bladder Cancer – Journal of Urology Commentary: Intravesical chemotherapy combination provides effective treatment alternative for high-risk non-muscle invasive bladder cancer – Wolters Kluwer